<html>
<head>
<meta charset="UTF-8"/>
<meta name="tikaGenerated" content="true"/>
<meta name="date" content="2015-11-19T00:04:02Z"/>
<meta name="xmp:CreatorTool" content="PDFCreator Version 1.7.3"/>
<meta name="Keywords" content="Public - I2 - A1"/>
<meta name="dc:creator" content="rallde01"/>
<meta name="dcterms:created" content="2015-11-19T00:04:02Z"/>
<meta name="Last-Modified" content="2015-11-19T00:04:02Z"/>
<meta name="dcterms:modified" content="2015-11-19T00:04:02Z"/>
<meta name="title" content="TP-L3-417 v1.1 November 2015 FLEBOGAMMA 5% administration guidelines"/>
<meta name="Last-Save-Date" content="2015-11-19T00:04:02Z"/>
<meta name="meta:save-date" content="2015-11-19T00:04:02Z"/>
<meta name="dc:title" content="TP-L3-417 v1.1 November 2015 FLEBOGAMMA 5% administration guidelines"/>
<meta name="modified" content="2015-11-19T00:04:02Z"/>
<meta name="Content-Type" content="application/pdf"/>
<meta name="creator" content="rallde01"/>
<meta name="meta:author" content="rallde01"/>
<meta name="dc:subject" content="Public - I2 - A1"/>
<meta name="meta:creation-date" content="2015-11-19T00:04:02Z"/>
<meta name="created" content="Thu Nov 19 10:34:02 ACDT 2015"/>
<meta name="xmpTPg:NPages" content="2"/>
<meta name="Creation-Date" content="2015-11-19T00:04:02Z"/>
<meta name="meta:keyword" content="Public - I2 - A1"/>
<meta name="Author" content="rallde01"/>
<meta name="producer" content="GPL Ghostscript 9.10"/>
</head>
<body>
<pre>
FLEBOGAMMA  5% DIF Intravenous Immunoglobulin 
 

FLEBOGAMMA  5% DIF is a human intravenous (IV) immunoglobulin (IVIg) solution for IV infusion. 
It is available in Australia as 2.5 g (50 mL), 5 g (100 mL), 10 g (200 mL) &amp; 20 g (400 mL) vials. 
Always read the Product Information (PI) in the box carefully before commencing. 
WARNING! DO NOT administer FLEBOGAMMA  5% DIF using infusion protocols for 
FLEBOGAMMA  10% DIF or ANY other brands of IVIg (including PRIVIGEN  10% &amp; INTRAGAM  P 6%). 

 

 

STORAGE 
? FLEBOGAMMA  5% DIF must be stored below 

30 C or refrigerated in a monitored blood fridge 
(in transfusion service where available). 

? It must not be stored in domestic/ward refrigerator. 
? Do not freeze. 
? Removal from storage must be documented in the 

register or electronic system for the purposes of 
tracking as per health service procedures/ 
transfusion service provider requirements. 

? Do not use after the expiry date. 
? Store protected from the light. 
? FLEBOGAMMA  5% DIF contains no antimicrobial 

preservative. Use in 1 patient, on 1 occasion only. 
? Contact transfusion service provider/product 

provider for advice re handling/return of any 
unused bottles (unopened). 

? Used bottles MUST be discarded in medical waste 
and are not suitable for recycling. 

VISUALLY INSPECT PRODUCT 
? FLEBOGAMMA  5% DIF should be a clear or 

slightly opalescent, colourless to pale yellow liquid. 
? Do not use solutions that are cloudy or have 

deposits (any sediment or particles) - contact the 
transfusion service provider. 

CONTRAINDICATIONS &amp; PRECAUTIONS 
? Always refer to the full PI. 
? Patients with rare total IgA deficiency should have 

the IVIg product with the lowest IgA content - 
INTRAGAM  P 6% is the preferred product. 

? Contraindicated in those with known 
hypersensitivity to this product. 

? Product contains 50 mg/mL of sorbitol as excipient. 
? WARNING! Contraindicated in patients with rare 

hereditary problems of fructose intolerance. 
? Babies &amp; young children should NOT 

receive this product as hereditary fructose 
intolerance may not yet be diagnosed &amp; may 
be fatal. 

? SA Immunoglobulin Therapy Advisory Group 
has determined that this product will NOT 
be issued to children under 5 years old. 

? Interferences with determination of blood glucose 
levels are not expected. 

PRIOR TO ADMINISTRATION 
? Correct reversible risk factors for adverse reactions (such as 

dehydration) before infusion is given. 
? Ensure prescription is complete including the BRAND &amp; 

CONCENTRATION of IVIg prescribed. 
? Check informed consent is documented as per health 

service policy. 
? Explain procedure to patient, including symptoms of possible 

reactions. 
? Ensure IV access patent. 
? Record baseline observations (TPR &amp; BP) &amp; general patient 

status including pre-existing rashes. 
? Ensure circumstances/situation appropriate to proceed. 
? Check resuscitation equipment, including oxygen and 

adrenaline are available &amp; in working order. 
? Read the PI contained in the box. 
? Allow the product to reach room temperature. 

ENSURE RIGHT PATIENT- RIGHT PRODUCT 
? WARNING! Verify correct patient, product (including brand 

&amp; concentration) &amp; prescription. 
? The patient s identify MUST always be confirmed prior to 

administration. 
? Check as per IV medication/health service policy. 

DOCUMENTATION OF BATCH NUMBER 
? All product batch numbers must be documented in the 

patient s medical record   the vials have a peel off label with 
the batch number. 

? The transfusion service provider may also attach peel off 
label(s). 

IV LINE/PUMPS 
? The use of a pump is recommended to ensure constant 

delivery of accurate rates. 
? A new standard IV line or blood administration set 

(170 - 200 micron filter) may be used. 
? Administration from a glass bottle requires a vented system. 

MEDICATION/OTHER IV FLUIDS 
? CAUTION! Do not mix or piggy back this product with other 

medications or IV fluids. 
? Administered via a separate IV line. 
? Premedication may be prescribed (e.g. for a history of 

reaction as per treating doctor). 
? Consider clearing the line with 0.9% Sodium Chloride 

solution (Normal Saline) on completion of infusion. 
 

Disclaimer: This is a guide only and the information contained herein is general in nature and does not correspond to or reflect any 
particular patient's circumstances or condition(s). It is not a substitute for expert opinion and/or clinical advice. Each of the parties involved 
in developing this document expressly disclaims and accepts no responsibility for any undesirable consequences arising from relying on 
the information, products, procedures or services referred to herein. 

 

Produced by SA BloodSafe Program, in conjunction with the SA Immunoglobulin Therapy Advisory Group, based on Australian Product 
information. 

 

BloodSafe Guide to Administration, Public - I2 - A1                      TP-L3-417 v1.1   5/11/2015 Page 1 of 2 



FLEBOGAMMA  5% DIF Intravenous Immunoglobulin 
 

 

 

FLEBOGAMMA  5% DIF INFUSION RATES 
? Infusion rates should be calculated &amp; prescribed by the 

treating doctor. Use ideal body weight to calculate 
infusion rates in obese patients. 

? Start slowly, increase rate gradually only if tolerated. 
? If the line is not primed with IVIg, consider this volume in 

the timing of rate increases. 

FLEBOGAMMA  5% DIF INFUSION RATES 
NOTE: RATES# below are in mL/kg/hr: 

1.0 mL/kg/hr for 30 minutes 
2.0 mL/kg/hr for 30 minutes 
3.0 mL/kg/hr for 30 minutes 
4.0 mL/kg/hr for 30 minutes 
5.0 mL/kg/hr for 30 minutes with max. rate 500 mL/hr 

Routine use of higher rates is not recommended. 
#Lower max. rate of up to 4 mL/kg/hr (max. 300 mL/hr) 

is recommended in high risk patients e.g. 
&gt; 65 years; diabetics; obese; 
those with pre-existing or risk factors for: 
cardiac disease, renal failure or arterial or venous 
thromboembolism; 
those with hyperviscosity; paraprotein or dehydration 
(for more info see PI &amp; consult treating doctor). 

? In septic patients or those with multiple risk factors, 
discuss timing of IVIg administration with an expert. 

? During an infusion, subsequent vials may commence at 
same rate that the preceding vial finished. 

? Each bottle should be completed within 4 hours. 
? It is recommended that subsequent infusions are given 

according to the same protocol (consult treating doctor if 
there has been a change in health status or reaction to a 
previous infusion). 

REACTIONS 
? Tend to be related to the rate of the infusion &amp; are more 

common in certain patient groups - refer to PI. 
? Symptoms/signs may include: dyspnoea, wheezing, 

chest tightness, coughing, changes in blood pressure, 
tachycardia, flushing, fever, rigors, skin rash/urticaria, 
headache, vomiting, nausea &amp; abdominal &amp; back pain. 

REACTIONS (continued) 
? If a reaction does occur: 

? stop administration immediately 
? assess vital signs 
? notify the medical officer 
? provide emergency care as required. 

? For minor reactions (headache is most common) the 
infusion can often be restarted cautiously at a slower 
rate after the patient has improved clinically. 

? Follow your institutional procedure for reporting 
adverse events to IVIg. Inform your transfusion 
service/product provider. 

OBSERVATIONS 
Refer to health service policies/procedures for IVIg 
infusions, PI for any specific recommendations, as well as 
considering individual patient factors &amp; consulting with 
treating doctor. 
General recommendations: 
? Close observation is required &amp; patient s general 

status should be monitored regularly throughout the 
infusion. 

? A common approach is to take a TPR &amp; BP: 
? as a baseline prior to commencing 
? with each rate increase 
? hourly once maximum rate is achieved 
? on completion 
? if the patient experiences new or increased 

symptoms. 

OBSERVATION POST INFUSION 
The following patients should be monitored for 1 hour after 
completion of the infusion: 
? those who have not had IVIg before 
? those who have switched from another product 
? where there has been a long interval since the last 

infusion 
? where there has been a significant deterioration in 

health 
? those who have had a reaction to the current or 

previous infusion. 
Other patients should be observed for at least 20 minutes. 
See PI, health service procedures &amp; consult treating 
doctor. 

 

Disclaimer: This is a guide only and the information contained herein is general in nature and does not correspond to or reflect any 
particular patient's circumstances or condition(s). It is not a substitute for expert opinion and/or clinical advice. Each of the parties involved 
in developing this document expressly disclaims and accepts no responsibility for any undesirable consequences arising from relying on 
the information, products, procedures or services referred to herein. 

 

Produced by SA BloodSafe Program, in conjunction with the SA Immunoglobulin Therapy Advisory Group, based on Australian Product 
information. 

 

 

 

For updates see www.sahealth.sa.gov.au/bloodsafe 
 

 

 

 

 

BloodSafe Guide to Administration, Public - I2 - A1                      TP-L3-417 v1.1   5/11/2015 Page 2 of 2 


</pre>
</body>
</html>